title: [A new, more expensive agent against ovarian cancer. Worth its price?].
authors.affiliation: Gynekologisk onkologi, Universitetssjukhuset i Lund.
authors.forename: T
authors.initials: T
authors.lastname: Högberg
authors.forename: G
authors.initials: G
authors.lastname: Karlsson
authors.forename: M
authors.initials: M
authors.lastname: Ridderheim
authors.forename: K
authors.initials: K
authors.lastname: Boman
authors.forename: B
authors.initials: B
authors.lastname: Frankendal
authors.forename: G
authors.initials: G
authors.lastname: Horvath
authors.forename: B
authors.initials: B
authors.lastname: Sorbe
authors.forename: P
authors.initials: P
authors.lastname: Strang
authors.forename: P
authors.initials: P
authors.lastname: Rosenberg
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000191:economics / Q000627:therapeutic use*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000523:psychology; D017239:Paclitaxel / Q000191:economics / Q000627:therapeutic use*; D011788:Quality of Life; D013548:Sweden
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel
vernacular_title: Nytt, dyrare medel mot ovarialcancer. Ar det värt sitt pris?